May 2026. This article is part of CRN’s Associate Member Spotlight series and reflects the views, opinions, and expertise of the featured member company, The Ginger Network. The content is provided for informational purposes only and does not represent the views, positions, or policies of the Council for Responsible Nutrition. Learn more: easconsultinggroup.com
As AI becomes more integrated into regulated operations, FDA is beginning to signal how it expects companies to use these tools—particularly in quality and compliance environments.
A recent FDA Warning Letter highlights concerns around the “inappropriate use” of AI in manufacturing, specifically where firms relied on AI-generated content for GMP documentation without adequate human review, Dean Cirotta, president of EAS Consulting Group explains. While the case involved drug manufacturing, the implications extend more broadly to any FDA-regulated industry.
For dietary supplement manufacturers operating under 21 CFR Part 111, the takeaway is clear: AI can support—but not replace—qualified quality oversight. Documents such as specifications, SOPs, and master records must still be reviewed, verified, and approved by appropriately trained personnel before implementation.
For supplement companies exploring AI, this development underscores several key considerations:
- AI outputs are not compliance-ready: Generated content should be treated as a starting point, not a final deliverable.
- Quality unit responsibility remains unchanged: Regulatory accountability cannot be delegated to automated systems.
- Process validation and documentation rigor still apply: AI does not replace foundational GMP requirements.
As FDA continues to evaluate how emerging technologies are used in regulated environments, companies should ensure that any adoption of AI tools is accompanied by clear governance, internal review procedures, and trained personnel oversight.
EAS Consulting Group supports dietary supplement companies in navigating evolving regulatory expectations, including the integration of new technologies into compliant quality systems.
Learn more at easconsultinggroup.com or contact the team to discuss how to align innovation with regulatory expectations.